ALK and lung cancer: Over the last decade, clinical management and treatment of lung cancer patients has become more dependent on molecular classification using “driver” mutations that occur in genes, such as anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), and c-Ros oncogene 1 (ROS1) [3,4,5].